Pharmaxis Ltd (AU:SNT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Syntara Limited, a clinical stage drug development company listed on the ASX, is set to update investors in an upcoming webinar, highlighting its promising pipeline including the lead candidate SNT-5505 for myelofibrosis. The company is advancing several phase 2 studies in high unmet need areas, while also collaborating on treatments for neurodegenerative diseases and fibrosis. With a strong focus on innovation, Syntara aims to make significant strides in treating complex conditions.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
